NorthWest Biotherapeutics Inc (NWBO)

[marzan]

Agree with you that analysis of the progression image could be the reason for the delay. On the other hand if the OS counts are pretty bad, this repeat of image analysis might not be even necessary with the conclusion the trial failed. But while everyone is living longer, it becomes necessary to re-examine the progression images. Had they already reached much beyond 248 and now what they are doing is trying to recheck that number, then the Company should have already notified us because it is a material event to PR. My gut feeling is that we might not have hit the 248 count yet, imo.